Biogen Doubles Down On Alzheimer’s and Neuroscience With Sangamo Gene Regulation Deal
Deal Worth Up To $2.37bn
Executive Summary
As sector awaits its aducanumab filing with bated breath, Biogen invests again in early stage neuroscience.
You may also be interested in...
Deal Watch: Vir Partnering With Alnylam, WuXi On Coronavirus Treatments
US biotech expands 2017 collaboration with Alnylam and inks collaboration with WuXi. Plus deals involving AbbVie, Allergan, Amazon, Thermo Fisher, Qiagen, Boehringer Ingelheim, Trutino, Taiho, Arcus, Eisai, Fuji Yakuhin, Hikma, Glenmark, Hanmi, GC, Bayer, GW.
Editas And Allergan Launch World’s First In Vivo CRISPR Trial
Partners pioneer approach in rare disease in what will be pivotal year for CRISPR and gene-editing technologies.
BioMarin All Set For Hemophilia Gene Therapy Approval, But Is It Overestimating Demand?
Analysts forecast a slow climb towards peak sales of $2bn – but competitors could erode that figure.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports